Lilly Asia Ventures has led a $23.2m round for the digital diagnostics technology developer, investing alongside new and existing backers.

Sanofi and Mass General Brigham contributed to a round that pushed the immunotherapy developer's total funding to nearly $60m.

Cambrian Biopharma returned to back the immunotherapy developer's series B round, following its series A three months ago.

GV and Nextech contributed to a series B round that boosted the affordable pharmaceutical developer's overall funding to $750m.

Hepalink will exit the immune and inflammatory disease drug developer in an acquisition that could reach $1.45bn in size.

Lilly Asia Ventures, a regional corporate venturing subsidiary of pharmaceutical firm Eli Lilly, reinvested in a round set to accelerate development of Abbisko's cancer-focused drug candidates.

GV, MRL Ventures Fund and WuXi Healthcare Ventures participated in a series B round that lifted the small molecule therapy developer's overall funding to $120m.

Takeda Digital Ventures, Humana, McKesson Ventures and dRx Capital backed the online pharmacy platform developer's series B round.

Fidelity provided a $4.8m second tranche after a first close featuring KNC, Ohar Pharmaceutical, Spera Pharma, Kisco and SRD Holdings.

The healthcare product provider has promoted Lizzie Lee to lead portfolio development and market research at its corporate venturing unit.